J E Tcheng

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi request reprint Eptifibatide: a potent inhibitor of the platelet receptor integrin, glycoprotein IIb/IIIa
    - Tcheng
    Duke Clinical Research Institute Box 3275, Duke University Medical Center, Durham, NC 27710, USA
    Expert Opin Investig Drugs 8:1893-1905. 1999
  2. ncbi request reprint Update on Abciximab Readministration During Percutaneous Coronary Interventions
    - Madan
    Division of Cardiology, Department of Medicine, Duke University Medical Center, Box 3257, Durham, NC 27710, USA
    Curr Interv Cardiol Rep 2:244-249. 2000
  3. doi request reprint Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients
    James E Tcheng
    Duke University Medical Center, Durham, NC 27705, USA
    Am J Cardiovasc Drugs 12:83-91. 2012
  4. ncbi request reprint Debate of adjunctive pharmacology for percutaneous coronary intervention: anticoagulation and clopidogrel are not (always) enough
    James E Tcheng
    Duke University Health System, Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    J Interv Cardiol 19:456-63. 2006
  5. ncbi request reprint Abciximab readministration: results of the ReoPro Readministration Registry
    J E Tcheng
    Duke Clinical Research Institute, Durham, NC, USA
    Circulation 104:870-5. 2001
  6. ncbi request reprint Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study)
    J E Tcheng
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 88:1097-102. 2001
  7. ncbi request reprint After fibrinolysis: is cardiac catheterization the answer?
    James E Tcheng
    Division of Cardiovascular Medicine, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27705, USA
    J Am Coll Cardiol 48:1336-8. 2006
  8. ncbi request reprint Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial
    James E Tcheng
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Circulation 108:1316-23. 2003
  9. ncbi request reprint Ethics and equipoise: rationale for a placebo-controlled study design of platelet glycoprotein IIb/IIIa inhibition in coronary intervention
    James E Tcheng
    Duke Clinical Research Institute, Durham, NC
    J Interv Cardiol 16:97-105. 2003
  10. ncbi request reprint Saline infusion in excimer laser coronary angioplasty
    J E Tcheng
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Semin Interv Cardiol 1:135-41. 1996

Collaborators

Detail Information

Publications84

  1. ncbi request reprint Eptifibatide: a potent inhibitor of the platelet receptor integrin, glycoprotein IIb/IIIa
    - Tcheng
    Duke Clinical Research Institute Box 3275, Duke University Medical Center, Durham, NC 27710, USA
    Expert Opin Investig Drugs 8:1893-1905. 1999
    ..Future research will focus on alternative doses, infusion regimens and combinations with other therapies to improve further cardiovascular outcomes...
  2. ncbi request reprint Update on Abciximab Readministration During Percutaneous Coronary Interventions
    - Madan
    Division of Cardiology, Department of Medicine, Duke University Medical Center, Box 3257, Durham, NC 27710, USA
    Curr Interv Cardiol Rep 2:244-249. 2000
    ..This review summarizes the available clinical data and provides suggestions for safe abciximab readministration...
  3. doi request reprint Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients
    James E Tcheng
    Duke University Medical Center, Durham, NC 27705, USA
    Am J Cardiovasc Drugs 12:83-91. 2012
    ..This review highlights the current state of evidence-based antiplatelet therapy and provides guidance on appropriate use of prasugrel in cardiovascular medicine...
  4. ncbi request reprint Debate of adjunctive pharmacology for percutaneous coronary intervention: anticoagulation and clopidogrel are not (always) enough
    James E Tcheng
    Duke University Health System, Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    J Interv Cardiol 19:456-63. 2006
    ....
  5. ncbi request reprint Abciximab readministration: results of the ReoPro Readministration Registry
    J E Tcheng
    Duke Clinical Research Institute, Durham, NC, USA
    Circulation 104:870-5. 2001
    ..This registry was conducted to characterize the effects of repeated administration of abciximab during intervention...
  6. ncbi request reprint Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study)
    J E Tcheng
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 88:1097-102. 2001
    ..With the single-bolus regimen, however, there was an early loss of the inhibition of platelet aggregation before steady state was reached. Additional dose-exploration studies may further optimize eptifibatide dosing...
  7. ncbi request reprint After fibrinolysis: is cardiac catheterization the answer?
    James E Tcheng
    Division of Cardiovascular Medicine, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27705, USA
    J Am Coll Cardiol 48:1336-8. 2006
  8. ncbi request reprint Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial
    James E Tcheng
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Circulation 108:1316-23. 2003
    ..However, variations in trial designs, modest sample sizes, and limited long-term follow-up have precluded these studies from being definitive...
  9. ncbi request reprint Ethics and equipoise: rationale for a placebo-controlled study design of platelet glycoprotein IIb/IIIa inhibition in coronary intervention
    James E Tcheng
    Duke Clinical Research Institute, Durham, NC
    J Interv Cardiol 16:97-105. 2003
    ....
  10. ncbi request reprint Saline infusion in excimer laser coronary angioplasty
    J E Tcheng
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Semin Interv Cardiol 1:135-41. 1996
    ..The purpose of this paper is to review the development and application of the technique of saline infusion in the clinical practice of excimer laser coronary angioplasty...
  11. doi request reprint Stent parameters predict major adverse clinical events and the response to platelet glycoprotein IIb/IIIa blockade: findings of the ESPRIT trial
    James E Tcheng
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Circ Cardiovasc Interv 2:43-51. 2009
    ..Only limited data describe relationships between stent parameters (length and diameter), adverse events after percutaneous coronary intervention, and effects of platelet glycoprotein IIb/IIIa blockade by stent parameters...
  12. ncbi request reprint Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment
    J E Tcheng
    Duke Clinical Research Institute, Durham, NC, USA
    Am Heart J 139:S38-45. 2000
    ....
  13. ncbi request reprint Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group
    S D Berkowitz
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Am Coll Cardiol 32:311-9. 1998
    ....
  14. ncbi request reprint Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II
    B E Tardiff
    Duke Clinical Research Institute, Durham, North Carolina 27710, USA
    J Am Coll Cardiol 33:88-96. 1999
    ....
  15. ncbi request reprint Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial
    G E Hafley
    Duke Clinical Research Institute, PO Box 17969, Durham, NC 27705, USA
    JAMA 285:2468-73. 2001
    ..6% of the eptifibatide group vs 9.4% of the placebo group (HR, 0.91; 95% CI, 0.68-1.22; P =.51). CONCLUSION: Adjunctive eptifibatide therapy during coronary stent implantation provides benefit through 6-month follow-up...
  16. ncbi request reprint Eptifibatide in percutaneous coronary intervention. A review
    J P Dery
    Duke Clinical Research Institute and Duke University Medical Center, Durham, NC, USA
    Minerva Cardioangiol 50:531-46. 2002
    ..These landmark studies, which are the focus of this review, emphasize the importance of considering the use of GP IIb-IIIa inhibitors in all patients undergoing PCI...
  17. ncbi request reprint Outcomes following interventions in small coronary arteries with the use of hand-crimped Palmaz-Schatz stents
    M G Cohen
    Department of Medicine, Duke University Medical Center, and the Duke Clinical Research Institute, Durham, North Carolina 27710, USA
    Am J Cardiol 85:446-50. 2000
    ..However, target lesion revascularization in small vessels remains high. Development of antiproliferative strategies could improve long-term outcomes for small-vessel interventions...
  18. ncbi request reprint Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100
    Mina Madan
    Duke Clinical Research Institute, Durham, NC, USA
    Am Heart J 144:151-8. 2002
    ..We prospectively studied platelet function in 250 patients receiving abciximab or eptifibatide during PCI...
  19. ncbi request reprint Provisional stenting strategies: systematic overview and implications for clinical decision-making
    W J Cantor
    Duke Clinical Research Institute, Durham, North Carolina, USA
    J Am Coll Cardiol 36:1142-51. 2000
    ..Provisional stenting may potentially reduce costs and rates of in-stent restenosis without compromising the quality of health care delivery...
  20. ncbi request reprint Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention
    J C O'Shea
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 140:834-9. 2000
    ..However, even though stents are now implanted in >75% of percutaneous interventional procedures, only one study, a trial of the monoclonal antibody abciximab, has formally evaluated adjunctive GP IIb/IIIa inhibition in this setting...
  21. ncbi request reprint Comparative early and late outcomes after primary percutaneous coronary intervention in ST-segment elevation and non-ST-segment elevation acute myocardial infarction (from the CADILLAC trial)
    David A Cox
    Mid Carolina Cardiology, Charlotte, Durham, North Carolina, USA
    Am J Cardiol 98:331-7. 2006
    ..The adverse prognosis of patients with NSTEMI should be recognized and efforts made to decrease reperfusion times...
  22. ncbi request reprint Optimal duration of eptifibatide infusion in percutaneous coronary intervention (an ESPRIT substudy)
    Abdallah G Rebeiz
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 94:926-9. 2004
    ....
  23. ncbi request reprint GP IIb/IIIa blockade in elective percutaneous coronary intervention
    J P Dery
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA
    Curr Pharm Des 10:387-98. 2004
    ..The following review will discuss the scientific grounds and the principal controversies surrounding the use of these compounds in patients undergoing elective percutaneous coronary intervention...
  24. ncbi request reprint Laser wire for crossing chronic total occlusions: "learning phase" results from the U.S. TOTAL trial. Total Occlusion Trial With Angioplasty by Using a Laser Wire
    S N Oesterle
    Department of Medicine, Stanford University Medical Center, California 94305, USA
    Cathet Cardiovasc Diagn 44:235-43. 1998
    ..1%). This "learning phase" pilot study confirmed the feasibility of a laser guidewire in chronic total occlusions that are resistant to passage of conventional guidewires. An extended registry at these investigative sites is planned...
  25. ncbi request reprint Feasibility and implications of an early discharge strategy after percutaneous intervention with abciximab in acute myocardial infarction (the CADILLAC Trial)
    David E Kandzari
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Am J Cardiol 92:779-84. 2003
    ..Hospitalizations after primary PCI are so short, however, that efforts to accelerate discharge with abciximab appear unfeasible, and overall costs remain unchanged...
  26. ncbi request reprint Reduction of myocardial ischemic injury following coronary intervention (the MC-1 to Eliminate Necrosis and Damage trial)
    David E Kandzari
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Am J Cardiol 92:660-4. 2003
    ..These results support the evaluation of MC-1 in pivotal trials of patients at risk for developing myocardial ischemia, infarction, or reperfusion injury...
  27. ncbi request reprint From clinical pathways to CPOE: challenges and opportunities in standardization and computerization of postoperative orders for total joint replacement
    Thomas H Vikoren
    Division of Orthopaedic Surgery, Box 3000, Orange Zone, Duke South Hospital, Trent Drive, Durham, NC 27710, USA
    J Surg Orthop Adv 15:195-200. 2006
    ..This article describes the authoring and implementation of a computerized order process for the care of postoperative total joints patients using a multidisciplinary approach...
  28. ncbi request reprint Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials
    David E Kandzari
    Division of Cardiology, Department of Medicine, Duke University Medical Center and Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 147:457-62. 2004
    ....
  29. ncbi request reprint Incidence and predictors of major vascular complications after percutaneous coronary intervention in the glycoprotein IIb/IIIa platelet inhibitor era
    Richard Konstance
    Duke University Medical Center, Durham, North Carolina, USA
    J Interv Cardiol 17:65-70. 2004
    ..The incidence of major vascular complications in this large, single-center study from the GP IIb/IIIa inhibitor era is consistent with data from the pre-GP IIb/IIIa inhibitor era and recent randomized trials...
  30. ncbi request reprint Influence of admission and discharge aspirin use on survival after primary coronary angioplasty for acute myocardial infarction
    David E Kandzari
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Am J Cardiol 94:1029-33. 2004
    ..We examined the effect of aspirin use at the time of admission and discharge from a large-scale, prospective multicenter trial of patients who had been treated with primary percutaneous coronary intervention in acute myocardial infarction...
  31. ncbi request reprint Relationship between infarct artery location, epicardial flow, and myocardial perfusion after primary percutaneous revascularization in acute myocardial infarction
    David E Kandzari
    Department of Medicine, Duke University Medical Center, Duke Clinical Research Institute, Durham, NC, USA
    Am Heart J 151:1288-95. 2006
    ..We examined the infarct artery-specific impact of epicardial and myocardial flow and reperfusion after primary PCI for acute myocardial infarction...
  32. ncbi request reprint Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention
    J Conor O'Shea
    Duke Clinical Research Institute, PO Box 17969, Durham, NC 27705
    JAMA 287:618-21. 2002
    ....
  33. ncbi request reprint Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions
    David F Kong
    Division of Cardiology, Department of Medicine, Duke University Medical Center and Clinical Research Institute, Durham, NC 27710, USA
    Am J Cardiol 92:651-5. 2003
    ..There also is increasing evidence that mortality reductions are preserved at 6 months...
  34. ncbi request reprint Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT Trial)
    Donal N Reddan
    Division of Nephrology and Duke Institute for Renal Outcomes and Health Policy, Durham, North Carolina 27705, USA
    Am J Cardiol 91:17-21. 2003
    ..94). An accompanying increase in bleeding risk also was not apparent with lower CrCl. The treatment effect of eptifibatide is realized regardless of renal function and trends toward being greater in patients with mild renal impairment...
  35. ncbi request reprint Coronary artery stents: evaluating new designs for contemporary percutaneous intervention
    David E Kandzari
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27710, USA
    Catheter Cardiovasc Interv 56:562-76. 2002
    ..The purpose of this review is to describe recent developments in stent design, examine the results of clinical trials of contemporary stents, and present future directions for investigation of new stent technologies...
  36. ncbi request reprint Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial
    Thaddeus R Tolleson
    Duke University Medical Center and Clinical Research Institute, Durham, NC 27705, USA
    J Am Coll Cardiol 41:386-93. 2003
    ..We evaluated the relationship between the degree of heparin anticoagulation and clinical efficacy and bleeding in patients undergoing contemporary percutaneous coronary intervention (PCI) with stent implantation...
  37. ncbi request reprint Eptifibatide: a potent inhibitor of the platelet receptor integrin glycoprotein IIb/IIIa
    J Conor O'Shea
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Expert Opin Pharmacother 3:1199-210. 2002
    ..Future research will focus on alternative clinical applications and combinations with other therapies to further improve cardiovascular outcomes...
  38. ncbi request reprint Current multicentre studies with the excimer laser: design and aims
    J E Tcheng
    Duke University Medical Center, Durham, NC 27710, USA
    Lasers Med Sci 16:122-9. 2001
    ..This article describes the rationale and objectives of these new approaches to some of the more challenging problems in cardiovascular disease...
  39. ncbi request reprint Final results of the ReoPro readministration registry
    Jean Pierre Dery
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 93:979-84. 2004
    ..However, the rate of severe and profound TCP is increased relative to first-time administration, particularly when the time between treatments is <30 days or when HACA is present...
  40. ncbi request reprint Impact of treatment delays on outcomes of primary percutaneous coronary intervention for acute myocardial infarction: analysis from the CADILLAC trial
    Bruce R Brodie
    LeBauer Cardiovascular Research Foundation and Moses Cone Heart and Vascular Center, Greensboro, NC, USA
    Am Heart J 151:1231-8. 2006
    ..The impact of treatment delays on outcomes after primary percutaneous coronary intervention for acute myocardial infarction is controversial...
  41. ncbi request reprint Which is the true channel?
    Abdul R Halabi
    Department of Medicine, Division of Interventional Cardiology, Duke University Medical Center, Durham, North Carolina, USA
    J Invasive Cardiol 16:716-8. 2004
  42. ncbi request reprint Acute myocardial infarction in a young male while playing paintball
    Svati H Shah
    Duke University Medical Center, Durham, NC, 27710, USA
    J Invasive Cardiol 14:713-5. 2002
  43. ncbi request reprint Outcomes following elective percutaneous coronary intervention without on-site surgical backup in a community hospital
    Alexander Paraschos
    Alamance Regional Medical Center, Burlington, North Carolina, USA
    Am J Cardiol 95:1091-3. 2005
    ..0%) had in-hospital complications, and 4 (0.8%) were urgently transferred. It is concluded that elective PCI with off-site surgical backup is feasible and safe for selected patients under specific conditions...
  44. ncbi request reprint Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction--the smoker's paradox revisited
    Giora Weisz
    Cardiovascular Research Foundation and Center for Interventional Therapy, New York, NY, USA
    Am Heart J 150:358-64. 2005
    ..We sought to determine the relationship between cigarette smoking and outcomes after mechanical reperfusion therapy in acute myocardial infarction (AMI)...
  45. ncbi request reprint Impact and determinants of left ventricular function in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction
    Amir Halkin
    Cardiovascular Research Foundation, New York, New York, USA
    Am J Cardiol 96:325-31. 2005
    ..Simple clinical and angiographic features readily available at the time of primary angioplasty also predict convalescent LVEF and are thus of prognostic utility...
  46. ncbi request reprint Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction
    Eugenia Nikolsky
    Columbia University Medical Center and Cardiovascular Research Foundation, New York, New York, USA
    Am J Cardiol 96:474-81. 2005
    ..0% vs 3.9%, p = 0.03) in patients who developed thrombocytopenia. In conclusion, thrombocytopenia that develops after primary PCI for AMI, although uncommon, is associated with increased hemorrhagic complications and decreased survival...
  47. ncbi request reprint Outcomes of patients consented but not randomized in a trial of primary percutaneous coronary intervention in acute myocardial infarction (the CADILLAC registry)
    Amir Halkin
    Cardiovascular Research Foundation, New York, New York, USA
    Am J Cardiol 96:1649-55. 2005
    ..Nonetheless, the overall survival of patients who were referred for primary PCI was excellent, and performance of primary PCI versus medical therapy was associated with increased survival among excluded patients...
  48. ncbi request reprint Bailout use of platelet glycoprotein IIb-IIIa inhibition during coronary stent implantation: observations from the ESPRIT trial
    Warren J Cantor
    Division of Cardiology, St Michael s Hospital, 30 Bond Street, Toronto, Ontario, Canada, M5B 1W8
    J Invasive Cardiol 17:360-4. 2005
    ..64). The need for bailout cannot be reliably predicted using baseline characteristics. Patients experiencing complications have poor clinical outcomes despite bailout use of GP IIb/IIIa inhibitors...
  49. ncbi request reprint In-hospital costs of coronary stent implantation with and without eptifibatide (the ESPRIT Trial). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin
    David J Cohen
    Cardiovascular Division, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Am J Cardiol 89:61-4. 2002
  50. ncbi request reprint Relationship between patient's risk profile and benefits in mortality from adjunctive abciximab to mechanical revascularization for ST-segment elevation myocardial infarction: a meta-regression analysis of randomized trials
    Giuseppe De Luca
    J Am Coll Cardiol 47:685-6. 2006
  51. ncbi request reprint Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting: insights from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trial
    Joseph A Puma
    New York Methodist Hospital Cornell Heart Center, Brooklyn New York 11215, USA
    J Am Coll Cardiol 47:715-8. 2006
    ..In order to determine a differential benefit from treatment, we compared the long-term outcome of high-risk versus low-risk patients and evaluated survival free from death or myocardial infarction at one year...
  52. ncbi request reprint Usefulness of routine unfractionated heparin infusion following primary percutaneous coronary intervention for acute myocardial infarction in patients not receiving glycoprotein IIb/IIIa inhibitors
    Kishore J Harjai
    Guthrie Clinic, Sayre, Pennsylvania, USA
    Am J Cardiol 99:202-7. 2007
    ..However, in a subset of patients treated with PTCA, postprocedural heparin use was independently associated with fewer in-hospital and 1-year MACEs...
  53. ncbi request reprint Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial
    Jean Pierre Dery
    Department of Cardiology, The Quebec Heart and Lung Institute, Quebec, Canada
    Catheter Cardiovasc Interv 70:43-50. 2007
    ..This analysis sought to investigate the complementary effect of thienopyridine pretreatment and platelet glycoprotein (GP) IIb/IIIa integrin blockade in coronary stent intervention...
  54. ncbi request reprint Relationship of creatine kinase-myocardial band release to Thrombolysis in Myocardial Infarction perfusion grade after intracoronary stent placement: an ESPRIT substudy
    C Michael Gibson
    Harvard Clinical Research Institute, 900 Commonwealth Ave, 2nd Floor, Boston, MA 02215, USA
    Am Heart J 143:106-10. 2002
    ..Given the high rates of Thrombolysis in Myocardial Infarction (TIMI) grade 3 flow after PCI, we hypothesized that abnormalities in tissue level perfusion would instead explain CK-MB release...
  55. ncbi request reprint Effectiveness and safety of reduced-dose enoxaparin in non-ST-segment elevation acute coronary syndrome followed by antiplatelet therapy alone for percutaneous coronary intervention
    Scott J Denardo
    University of Florida, Gainesville, FL, USA
    Am J Cardiol 100:1376-82. 2007
    ....
  56. ncbi request reprint Impact of ST-segment resolution after primary angioplasty on outcomes after myocardial infarction in elderly patients: an analysis from the CADILLAC trial
    Abhiram Prasad
    Division of Cardiovascular Diseases and Department of Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minn, USA
    Am Heart J 147:669-75. 2004
    ..Whether lower rates of reperfusion success contribute to the poor prognosis in elderly patients is unknown...
  57. ncbi request reprint Intracoronary bolus administration of eptifibatide during percutaneous coronary stenting for non ST elevation myocardial infarction and unstable angina
    Albert J Deibele
    Division of Cardiology, Duluth Clinic, Duluth, Minnesota, USA
    J Thromb Thrombolysis 22:47-50. 2006
    ....
  58. doi request reprint Review of the 2005 American College of Cardiology, American Heart Association, and Society for Cardiovascular Interventions guidelines for adjunctive pharmacologic therapy during percutaneous coronary interventions: practical implications, new clinical da
    Peter J Casterella
    Utah Heart Clinic, Salt Lake City, UT, USA
    Am Heart J 155:781-90. 2008
    ....
  59. ncbi request reprint Impact of baseline platelet count in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction (from the CADILLAC trial)
    Eugenia Nikolsky
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York, USA
    Am J Cardiol 99:1055-61. 2007
    ..03, 95% CI 1.00 to 1.06, p = 0.055) at 1 year. In conclusion, a higher baseline platelet count in patients with AMI is a powerful independent predictor of death and reinfarction within the first year after primary PCI...
  60. ncbi request reprint Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials
    Giuseppe De Luca
    Isala Klinieken, Hospital De Weezenlanden, Zwolle, The Netherlands
    JAMA 293:1759-65. 2005
    ..The benefits of abciximab in patients with ST-segment elevation myocardial infarction (STEMI) are still a matter of debate...
  61. ncbi request reprint Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) tr
    Alexandra J Lansky
    College of Physicians and Surgeons, Columbia University, and the Cardiovascular Research Foundation, New York, NY 10022, USA
    Circulation 111:1611-8. 2005
    ..Whether contemporary interventional treatment strategies have improved outcomes for women compared with men is unknown...
  62. ncbi request reprint Closure devices and vascular complications among percutaneous coronary intervention patients receiving enoxaparin, glycoprotein IIb/IIIa inhibitors, and clopidogrel
    J Emilio Exaire
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Catheter Cardiovasc Interv 64:369-72. 2005
    ..While minor and major TIMI bleeding remained very low in both groups, CD was associated with a twofold increase in risk of any-bleeding event when compared to MC, especially when using GP IIb/IIIa inhibitors...
  63. ncbi request reprint Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction
    H Mehrdad Sadeghi
    William Beaumont Hospital, Royal Oak, Mich, USA
    Circulation 108:2769-75. 2003
    ..The prognostic importance of renal insufficiency (RI) in patients undergoing primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) has not been well characterized...
  64. ncbi request reprint Cost-effectiveness of coronary stenting and abciximab for patients with acute myocardial infarction: results from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trial
    Ameet Bakhai
    Harvard Clinical Research Institute, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, Mass 02215, USA
    Circulation 108:2857-63. 2003
    ..Both stenting and the glycoprotein IIb/IIIa inhibitor abciximab improve outcomes for patients undergoing primary angioplasty for acute myocardial infarction (AMI). However, the cost-effectiveness of these strategies is unknown...
  65. ncbi request reprint Platelet inhibition strategies in percutaneous coronary intervention: competition or coopetition?
    James E Tcheng
    J Am Coll Cardiol 42:1196-8. 2003
  66. ncbi request reprint Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, an
    Wayne B Batchelor
    Tallahassee Heart and Vascular Institute, Tallahassee Memorial Healthcare, Tallahassee, Fla 32308, USA
    Circulation 106:1470-6. 2002
    ..The relative anti-aggregatory effects of currently prescribed platelet glycoprotein IIb/IIIa receptor antagonists during and after percutaneous coronary intervention for acute coronary syndromes have not been established...
  67. ncbi request reprint Outcomes of optimal or "stent-like"balloon angioplasty in acutemyocardial infarction: the CADILLAC trial
    David A Cox
    Mid Carolina Cardiology, Charlotte, North Carolina 28204, USA
    J Am Coll Cardiol 42:971-7. 2003
    ....
  68. ncbi request reprint Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization
    Eric J Topol
    Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Am J Med 113:1-6. 2002
    ..Brief intervention with this monoclonal antibody during percutaneous coronary revascularization is associated with significant improvement of long-term survival...
  69. ncbi request reprint Double negatives
    David E Kandzari
    Am Heart J 145:9-11. 2003
  70. ncbi request reprint Efficacy and safety of minimal dose (< or =1,000 units) unfractionated heparin with abciximab in percutaneous coronary intervention
    Scott J Denardo
    Cardiac Catheterization Laboratory, FirstHealth of Carolinas Moore Regional Hospital, Pinehurst, North Carolina 28374, USA
    Am J Cardiol 91:1-5. 2003
    ....
  71. ncbi request reprint Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT)
    M Ashequl Islam
    Geisinger Medical Center, Danville, Pennsylvania 17822, USA
    Am J Cardiol 90:916-21. 2002
    ..5% vs 10.7%; p = 0.007). In summary, abciximab (compared with placebo) significantly reduced angiographic complications during coronary stenting. Abciximab also prevented CK-MB elevations in patients without angiographic complications...
  72. ncbi request reprint Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction
    Gregg W Stone
    Cardiovascular Research Foundation and Lenox Hill Heart and Vascular Institute, New York, NY 10022, USA
    N Engl J Med 346:957-66. 2002
    ..When used in combination with PTCA, coronary stenting and platelet glycoprotein IIb/IIIa inhibitors may further improve outcomes...
  73. ncbi request reprint Importance of mitral regurgitation inpatients undergoing percutaneous coronary intervention for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial
    Gregory G Pellizzon
    Mid America Heart Institute, Saint Luke s Hospital, Kansas City, Missouri, USA
    J Am Coll Cardiol 43:1368-74. 2004
    ..We sought to determine the prognostic importance of mitral regurgitation (MR) in patients undergoing percutaneous coronary intervention for acute myocardial infarction (AMI)...
  74. ncbi request reprint Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial
    Giulio Guagliumi
    Ospedali Riuniti di Bergamo, Bergamo, Italy
    Circulation 110:1598-604. 2004
    ....
  75. ncbi request reprint Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction
    Paul Sorajja
    The Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Eur Heart J 26:667-74. 2005
    ..We sought to determine whether the combination of SigmaSTR and MB after primary percutaneous coronary intervention (PCI) in AMI has greater prognostic utility than either measure alone...
  76. ncbi request reprint Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy
    Scott J Denardo
    Cardiac Catheterization Laboratory, FirstHealth of Carolinas Moore Regional Hospital, Pinehurst, NC 28374, USA
    Am Heart J 149:138-44. 2005
    ....
  77. ncbi request reprint Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial)
    Thomas D Stuckey
    LeBauer Cardiovascular Research Foundation and Moses Cone Heart and Vascular Center, Greensboro, North Carolina 27401, USA
    Am J Cardiol 95:1-7. 2005
    ....
  78. ncbi request reprint A comparison of clinical outcomes between Canadian and American patients after nonurgent coronary stenting
    Mina Madan
    Sunnybrook and Women s College Health Sciences Centre, Toronto, Ontario, Canada
    Can J Cardiol 20:1343-9. 2004
    ..Few data are available comparing PCI outcomes between the two countries in the era of coronary stenting and adjunctive glycoprotein IIb/IIIa inhibition...
  79. ncbi request reprint Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction
    Costantino O Costantini
    Cardiovascular Research Foundation and Lenox Hill Hospital, New York, New York, USA
    J Am Coll Cardiol 44:305-12. 2004
    ..We sought to determine the prognostic importance of myocardial reperfusion after various contemporary interventional strategies in patients with acute myocardial infarction (AMI)...
  80. ncbi request reprint Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial)
    George Dangas
    Cardiovascular Research Foundation and Columbia University Medical Center, New York, New York, USA
    Am J Cardiol 94:983-8. 2004
    ..The incidence of early thrombosis after primary angioplasty and stenting is decreased by abciximab use...
  81. ncbi request reprint Prognostic utility of comparative methods for assessment of ST-segment resolution after primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial
    Michael G McLaughlin
    Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    J Am Coll Cardiol 44:1215-23. 2004
    ..This study was done to assess and compare the prognostic significance of multiple methods for measuring ST-segment elevation resolution (STR) following primary percutaneous coronary intervention (PCI)...
  82. ncbi request reprint Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial
    Eugenia Nikolsky
    Cardiovascular Research Foundation, New York, New York 10022, USA
    J Am Coll Cardiol 44:547-53. 2004
    ..We sought to investigate the impact of anemia in patients with acute myocardial infarction (AMI) undergoing primary percutaneous coronary intervention (PCI)...
  83. ncbi request reprint Temporal spectrum of ischemic complications with percutaneous coronary intervention: the ESPRIT experience
    Warren J Cantor
    St Michael s Hospital, Division of Cardiology, 30 Bond Street, Toronto, Ontario, Canada, M44 1W8
    J Invasive Cardiol 16:475-81. 2004
    ..Post-procedural MI is often not detected until greater than or equal to 12 hours after PCI. Treatment with a glycoprotein IIb/IIIa inhibitor is the only modifiable parameter that reduces the risk for early ischemic complications...
  84. ncbi request reprint Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?. Lessons from the ESPRIT study
    Laura S Fernandes
    Baylor College of Medicine and The Methodist DeBakey Heart Center, Houston Texas 77030, USA
    J Am Coll Cardiol 40:1085-91. 2002
    ..The study was done to determine whether eptifibatide, a platelet glycoprotein (GP) IIb/IIIa antagonist, prevents ischemic complications following percutaneous coronary interventions (PCIs) in women as well as in men...